Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $356

Benzinga · 2d ago
Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $326 to $356.